老虎证券

BRIEF-Biogen’S Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation For The Treatment Of Alzheimer’S Disease

Reuters
04-02
BRIEF-Biogen’S Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation For The Treatment Of Alzheimer’S Disease

April 2 (Reuters) - Biogen Inc BIIB.O:

  • BIOGEN’S INVESTIGATIONAL TAU-TARGETING THERAPY BIIB080 RECEIVES FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF ALZHEIMER’S DISEASE

  • BIOGEN: PHASE 2 CELIA STUDY IS NOW FULLY ENROLLED, WITH A DATA READOUT EXPECTED IN 2026

Source text: ID:nGNX4mzfYS

Further company coverage: BIIB.O

(((( Reuters.briefs@thomsonreuters.com ;));))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10